Ftse Mib
32.665,21
-2,81%
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
66.318,22
-0,48%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Europa EU Mithra Pharmaceuticals SA (MITRA) Mithra Pharmaceuticals SA (MITRA) Notizie

MITRA

Mithra Pharmaceuticals (MITRA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:MITRA
DataOraFonteTitoloSimboloCompagnia
28/05/202415:41GlobeNewswire Inc.Mithra postpones its annual general meetingEU:MITRAMithra Pharmaceuticals SA
03/05/202417:30GlobeNewswire Inc.Mithra enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization processEU:MITRAMithra Pharmaceuticals SA
29/04/202407:00GlobeNewswire Inc.Mithra updates on offers received in the context of its monetization process and on its Annual Report 2023EU:MITRAMithra Pharmaceuticals SA
22/04/202407:00GlobeNewswire Inc.Mithra secures court protection measures to advance monetization processEU:MITRAMithra Pharmaceuticals SA
08/03/202407:00GlobeNewswire Inc.Mithra reports full year 2023 financial resultsEU:MITRAMithra Pharmaceuticals SA
05/03/202407:01GlobeNewswire Inc.Mithra announces changes to its executive managementEU:MITRAMithra Pharmaceuticals SA
05/03/202407:00GlobeNewswire Inc.Mithra initiates monetization process, receives bridge loan from existing lendersEU:MITRAMithra Pharmaceuticals SA
29/02/202411:42GlobeNewswire Inc.DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phaseEU:MITRAMithra Pharmaceuticals SA
15/02/202418:23GlobeNewswire Inc.Mithra sells shares in Mayne PharmaEU:MITRAMithra Pharmaceuticals SA
06/02/202407:00GlobeNewswire Inc.Mithra updates on cash positionEU:MITRAMithra Pharmaceuticals SA
21/12/202317:45GlobeNewswire Inc.Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in IsraelEU:MITRAMithra Pharmaceuticals SA
20/12/202317:45GlobeNewswire Inc.Mithra Completes Pediatric Study of ESTELLE® in Adolescent PatientsEU:MITRAMithra Pharmaceuticals SA
18/12/202307:00GlobeNewswire Inc.Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 TrialEU:MITRAMithra Pharmaceuticals SA
04/12/202307:00GlobeNewswire Inc.Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in ChinaEU:MITRAMithra Pharmaceuticals SA
30/11/202307:00GlobeNewswire Inc.Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United StatesEU:MITRAMithra Pharmaceuticals SA
28/11/202317:45GlobeNewswire Inc.Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in AmsterdamEU:MITRAMithra Pharmaceuticals SA
07/11/202307:00GlobeNewswire Inc.Mithra’s NEXTSTELLIS® granted additional patent in the United StatesEU:MITRAMithra Pharmaceuticals SA
06/11/202318:52GlobeNewswire Inc.Mithra releases invitation to its extraordinary securities holders’ meetingEU:MITRAMithra Pharmaceuticals SA
26/10/202307:00GlobeNewswire Inc.Mithra and Searchlight Pharma sign DONESTA® licensing agreement for CanadaEU:MITRAMithra Pharmaceuticals SA
23/10/202307:00GlobeNewswire Inc.Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreementEU:MITRAMithra Pharmaceuticals SA
17/10/202307:00GlobeNewswire Inc.Mithra’s Board of Directors to propose the removal of its request for change of the remuneration policy at the Special General MeetingEU:MITRAMithra Pharmaceuticals SA
11/10/202307:15GlobeNewswire Inc.Shareholder LetterEU:MITRAMithra Pharmaceuticals SA
11/10/202307:00GlobeNewswire Inc.Mithra announces update to the agenda of its upcoming special general shareholders’ meetingEU:MITRAMithra Pharmaceuticals SA
10/10/202318:00GlobeNewswire Inc.Mithra to Hold Presentations on Key Role of Estrogens in Women’s Health, Including Estetrol (E4), at FIGO World CongressEU:MITRAMithra Pharmaceuticals SA
05/10/202307:00GlobeNewswire Inc.Mithra Provides an Update in the Context of Recent Market DevelopmentsEU:MITRAMithra Pharmaceuticals SA
27/09/202307:00GlobeNewswire Inc.Mithra Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen at NAMS 2023EU:MITRAMithra Pharmaceuticals SA
26/09/202307:00GlobeNewswire Inc.Mithra Financial Results for First-Half 2023EU:MITRAMithra Pharmaceuticals SA
22/09/202313:30GlobeNewswire Inc.Mithra présentera ses résultats financiers du premier semestre 2023 à ses investisseurs lors d'une conférence web le 26 septembre à 14 h 00 CETEU:MITRAMithra Pharmaceuticals SA
21/09/202317:55GlobeNewswire Inc.Information on the total number of voting rights (denominator)EU:MITRAMithra Pharmaceuticals SA
21/09/202317:55GlobeNewswire Inc.Mithra to Hold Investor Call on H1 2023 Financial Results on September 26 at 14:00 CESTEU:MITRAMithra Pharmaceuticals SA
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:MITRA

La tua Cronologia

BIT
P16K79
BNP Paribas Issuance
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network